跳至主要内容
临床试验/NCT07616128
NCT07616128招募中2 期

A Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of EVO756 for the Prevention of Migraine in Adults

Evommune, Inc.34 个研究点 分布在 1 个国家目标入组 330 人开始时间: 2026年7月29日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
招募中
入组人数
330
试验地点
34

研究概览

简要总结

This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 64 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Adults aged 18 to <65 years
  • Migraine with or without aura, per ICHD-3 criteria
  • History of failure with prior preventive migraine treatments
  • Not currently using migraine preventive therapy

排除标准

  • Difficulty distinguishing migraine from other headache types or presence of other primary headache disorders
  • Use of certain medications
  • Any clinically significant medical, psychiatric, neurological, cardiovascular, or laboratory abnormalities

研究组 & 干预措施

Dose 1

Experimental

Orally administered EVO756, Dose 1 (Daily)

干预措施: EVO756, Dose 1 (Drug)

Dose 2

Experimental

Orally administered EVO756, Dose 2 (Daily)

干预措施: EVO756, Dose 2 (Drug)

Placebo

Placebo Comparator

Placebo control (Daily)

干预措施: Placebo (Drug)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (34)

Loading locations...

相似试验